Basis for resistance to imatinib in 16 BCR-ABL mutants as determined using molecular dynamics

Tai Sung Lee, Steven J. Potts, Maher Albitar

Research output: Contribution to journalArticlepeer-review

8 Scopus citations


Large-scale (∼36,000 atoms) long-time (30 ns each) molecular dynamics (MD) simulations on the complex of imatinib and 16 common mutants of the ABL tyrosine kinase domain have been performed to study the imatinib resistance mechanisms at the atomic level. MD simulations show that long time computational simulations could offer insight information that static models, simple homology modeling methods, or short-time simulations cannot provide for the BCR-ABL imatinib resistance problem. Three possible types of mutational effects from those mutants are found: the direct effect on the contact interaction with imatinib (e.g. some P-loop mutations), the effect on the conformation of a remote region contacting with imatinib (e.g. T315I), and the effect on interaction between two regions within the BCR-ABL domain (e.g. H396P). Insights of possible imatinib resistance mechanisms, not consistent with current consensus, are revealed from various analyses and our findings suggest that drugs with different binding modes may be necessary to overcome the drug resistance due to T315I and other mutations. The relevant patents are discussed.

Original languageEnglish (US)
Pages (from-to)164-173
Number of pages10
JournalRecent Patents on Anti-Cancer Drug Discovery
Issue number2
StatePublished - 2009
Externally publishedYes

All Science Journal Classification (ASJC) codes

  • Oncology
  • Drug Discovery
  • Cancer Research
  • Pharmacology (medical)


  • Imatinib resistance
  • MD simulation
  • Molecular dynamics simulation


Dive into the research topics of 'Basis for resistance to imatinib in 16 BCR-ABL mutants as determined using molecular dynamics'. Together they form a unique fingerprint.

Cite this